A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study.
| Title: | A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer: The PANDA Study. |
|---|---|
| Authors: | Batman S; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Messick CA; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Milbourne A; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Guo M; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Munsell MF; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Fokom-Domgue J; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Salcedo M; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Deshmukh A; The University of Texas Health Science Center, Houston, Texas.; Dahlstrom KR; Baylor College of Medicine, Houston, Texas.; Ogburn M; The University of Texas Rio Grande Valley, Edinburg, Texas.; Price A; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Fleming ND; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Taylor J; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Shafer A; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Cobb L; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Sigel K; The Mount Sinai Hospital, New York, New York.; Sturgis EM; Baylor College of Medicine, Houston, Texas.; Chiao EY; The University of Texas MD Anderson Cancer Center, Houston, Texas.; Schmeler KM; The University of Texas MD Anderson Cancer Center, Houston, Texas. |
| Source: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2022 Dec 05; Vol. 31 (12), pp. 2185-2191. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9200608 Publication Model: Print Cited Medium: Internet ISSN: 1538-7755 (Electronic) Linking ISSN: 10559965 NLM ISO Abbreviation: Cancer Epidemiol Biomarkers Prev Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Philadelphia, PA : American Association for Cancer Research, c1991- |
| MeSH Terms: | Papillomavirus Infections*/complications ; Papillomavirus Infections*/epidemiology ; Papillomavirus Infections*/diagnosis ; Uterine Cervical Neoplasms*/diagnosis ; Uterine Cervical Neoplasms*/epidemiology ; Anus Neoplasms*/diagnosis ; Anus Diseases*/epidemiology ; Vulvar Neoplasms*/epidemiology ; Carcinoma in Situ*/epidemiology ; Squamous Intraepithelial Lesions*; Vagina/pathology ; Humans ; Female ; Cross-Sectional Studies ; Papillomaviridae ; Prevalence |
| Abstract: | Background: High-risk human papillomavirus (HR-HPV) infection is a risk factor for anal cancer, yet no anal cancer screening guidelines exist for women with lower genital tract HPV-related disease. We sought to describe the prevalence of anal HR-HPV or cytologic abnormalities in such women.; Methods: This cross-sectional study was performed between October 2018 and December 2021. Inclusion criteria were ≥21 years of age and a prior diagnosis of high-grade dysplasia/cancer of the cervix, vagina, or vulva. Participants underwent anal cytology and anal/cervicovaginal HR-HPV testing. Women with abnormal anal cytology were referred for high-resolution anoscopy (HRA).; Results: 324 evaluable women were enrolled. Primary diagnosis was high-grade dysplasia/cancer of the cervix (77%), vagina (9%), and vulva (14%). Anal HR-HPV was detected in 92 patients (28%) and included HPV-16 in 24 (26%), HPV-18 in 6 (7%), and other HR-HPV types in 72 (78%) patients. Anal cytology was abnormal in 70 patients (23%) and included atypical squamous cells of undetermined significance (80%), low-grade squamous intraepithelial lesion (9%), high-grade intraepithelial lesion (HSIL; 1%), and atypical squamous cells-cannot rule out HSIL (10%). Of these patients, 55 (79%) underwent HRA. Anal biopsies were performed in 14 patients: 2 patients had anal intraepithelial neoplasia (AIN) 2/3, 1 patient had AIN 1, and 11 patients had negative biopsies. Both patients with AIN 2/3 had a history of cervical dysplasia.; Conclusions: Our results suggest an elevated risk of anal HR-HPV infection and cytologic abnormalities in women with lower genital tract dysplasia/cancer.; Impact: These results add to the growing body of evidence suggesting the need for evaluation of screening methods for anal dysplasia/cancer in this patient population to inform evidence-based screening recommendations.; (©2022 American Association for Cancer Research.) |
| References: | Clin Infect Dis. 2020 Jul 11;71(2):390-399. (PMID: 31504329); Gynecol Oncol. 2016 Jun;141(3):492-496. (PMID: 27095188); Int J Epidemiol. 2017 Jun 1;46(3):924-938. (PMID: 27789668); Int J Cancer. 2021 Jan 1;148(1):38-47. (PMID: 32621759); Neoplasma. 2015;62(2):308-14. (PMID: 25591597); Obstet Gynecol. 2011 Mar;117(3):643-649. (PMID: 21343768); AIDS. 2020 Dec 1;34(15):2249-2258. (PMID: 32947592); Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1090-7. (PMID: 27358257); JAMA Netw Open. 2018 Sep 7;1(5):e181999. (PMID: 30646145); Am J Obstet Gynecol. 2015 Sep;213(3):278-309. (PMID: 25797230); Lancet Oncol. 2007 Apr;8(4):311-6. (PMID: 17395104); Dis Colon Rectum. 2019 Aug;62(8):934-940. (PMID: 30888979); J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):65-71. (PMID: 24419063); J Biomed Inform. 2019 Jul;95:103208. (PMID: 31078660); JAMA. 2002 Apr 24;287(16):2114-9. (PMID: 11966386); Nat Rev Dis Primers. 2016 Dec 01;2:16086. (PMID: 27905473); Obstet Gynecol. 2015 Dec;126(6):1294-1300. (PMID: 26551180); J Biomed Inform. 2009 Apr;42(2):377-81. (PMID: 18929686); J Natl Cancer Inst. 2021 Jun 1;113(6):792-796. (PMID: 32833021); J Low Genit Tract Dis. 2010 Oct;14(4):346-51. (PMID: 20885163); Diagn Cytopathol. 2011 May;39(5):323-7. (PMID: 21488174); Gynecol Oncol. 2019 May;153(2):266-270. (PMID: 30827725); Clin Infect Dis. 2020 Apr 10;70(8):1701-1707. (PMID: 31292602); J Infect Dis. 2022 Mar 23;:. (PMID: 35325151); Expert Rev Gastroenterol Hepatol. 2020 Aug;14(8):665-680. (PMID: 32458709) |
| Grant Information: | P30 CA016672 United States CA NCI NIH HHS; T32 CA101642 United States CA NCI NIH HHS |
| Entry Date(s): | Date Created: 20220920 Date Completed: 20221206 Latest Revision: 20230606 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9729427 |
| DOI: | 10.1158/1055-9965.EPI-22-0548 |
| PMID: | 36126275 |
| Database: | MEDLINE |
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't